文献速递妇科

上皮性卵巢癌分子谱分析的治疗现状

The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-10-11

综述指出,上皮性卵巢癌中50%的肿瘤存在同源重组修复基因损伤突变(即HRD),包括BRCA基因。所有卵巢癌患者均应转诊进行遗传咨询和胚系BRCA检测,无胚系BRCA突变者需评估体细胞BRCA突变,HRD检测可指导无BRCA突变患者的治疗选择。目前所有胚系或体细胞BRCA突变患者应接受PARP抑制剂一线维持治疗,2020年5月起HRD和HR功能正常肿瘤患者也可选择PARP抑制剂维持治疗。

要点

  • 所有卵巢癌患者均应转诊遗传咨询和胚系BRCA检测。
  • 无胚系BRCA突变者需评估体细胞BRCA突变。
  • 胚系或体细胞BRCA突变者应接受PARP抑制剂一线维持治疗。

核心结论

  • 分子肿瘤谱分析指导的靶向治疗已整合入多种实体瘤治疗指南,上皮性卵巢癌中BRCA突变和HRD是PARP抑制剂使用的预测生物标志物。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • 上皮性卵巢癌中50%的肿瘤存在同源重组修复基因损伤突变(即HRD),包括BRCA基因。
  • 多基因面板遗传检测可能比有限癌易感基因检测信息更丰富且更具成本效益。

关键数值与推荐

  • 所有卵巢癌患者必须转诊进行遗传咨询和胚系BRCA突变检测。
  • 无胚系有害BRCA突变患者必须评估体细胞BRCA突变。
  • HRD检测可帮助指导无BRCA突变女性的治疗选择。
  • 目前所有胚系或体细胞BRCA突变患者均应接受PARP抑制剂一线维持治疗。
  • 2020年5月,PARP抑制剂维持治疗选项扩展至HRD和HR功能正常肿瘤患者。

临床怎么用

  • 对每例上皮性卵巢癌患者常规转诊遗传咨询并检测胚系BRCA突变。
  • 无胚系BRCA突变者应补充体细胞BRCA检测,必要时行HRD检测以指导PARP抑制剂维持治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advances in next generation sequencing have allowed for rapid and economical germline and tumor genomic profiling. Targeted therapies based on molecular tumor profiling are now integrated into treatment guidelines for many solid tumors. In epithelial ovarian cancer, 50% of tumors possess damaging mutations in homologous recombination repair genes (aka homologous recombination deficiency or HRD) which includes the BRCA genes. Deleterious BRCA mutations and HRD have recently emerged as predictive biomarkers for the use of PARP inhibitors in ovarian cancer. Every patient with ovarian cancer must be referred for genetic counseling and germline testing for BRCA mutations. Multigene panel genetic testing may be more informative and cost-effective than limited testing of cancer susceptibility genes. Patients without a germline deleterious BRCA mutation must be assessed for a somatic BRCA mutation. Assays for HRD may help guide treatment options in women who do not have a BRCA mutation. Currently, all patients with a germline or somatic BRCA mutation should be offered upfront maintenance therapy with a PARP inhibitor. During May 2020, options for maintenance therapy with a PARP inhibitor were expanded to patients with HRD and HR-proficient tumors.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Haunschild CE, Tewari KS. The current landscape of molecular profiling in the treatment of epithelial ovarian cancer. Gynecol Oncol. 2020. PMID: 33055011. doi:10.1016/j.ygyno.2020.09.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。